TY - JOUR
TI - Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors
AU - Chatziralli, I.
AU - Sergentanis, T.
AU - Zagouri, F.
AU - Chrysikos, D.
AU - Ladas, I.
AU - Zografos, G.C.
AU - Moschos, M.
JO - The Breast Journal
PY - 2016
VL - 22
TODO - 5
SP - 561-563
PB - Blackwell Publishing Inc.
SN - 1075-122X, 1524-4741
TODO - 10.1111/tbj.12633
TODO - anastrozole;  exemestane;  letrozole;  aromatase inhibitor, adult;  Article;  best corrected visual acuity;  biomicroscopy;  blepharitis;  blurred vision;  breast cancer;  cancer hormone therapy;  cancer patient;  clinical article;  controlled clinical trial;  controlled study;  epiphora;  eye redness;  female;  foreign body;  human;  male;  meibomian gland dysfunction;  middle aged;  ocular surface disease;  ophthalmoscopy;  prevalence;  punctate keratitis;  slit lamp;  aged;  anterior eye segment;  Breast Neoplasms;  case control study;  chemically induced;  drug effects;  eye disease, Aged;  Anterior Eye Segment;  Aromatase Inhibitors;  Breast Neoplasms;  Case-Control Studies;  Eye Diseases;  Female;  Humans;  Middle Aged
TODO - Aromatase inhibitors (AIs) are widely used as adjuvant hormonal therapy in postmenopausal women with hormone receptor-positive breast cancer. The purpose of this study was to investigate the potential impact of AIs on the anterior segment of the eye and especially the ocular surface. Participants in our study were 41 hormone receptor-positive early stage breast cancer patients (80 eyes), treated with AIs, while 80 eyes of 40 age- and gender-matched healthy controls, not previously used AIs for any purpose, were also evaluated. All participants underwent a complete ophthalmological examination, including best corrected visual acuity (BCVA) assessment, slit-lamp biomicroscopy, and dilated fundus examination. Ocular surface disease-related symptoms and signs were also recorded. The most common symptom was found to be blurred vision, while other symptoms included foreign body sensation, tearing, redness, and photophobia. Slit-lamp examination revealed blepharitis and meibomian gland dysfunction in 75% and 42.5% of patients, respectively. Superficial punctate keratitis and conjunctival injection were also present. Our results demonstrated a high prevalence of ocular surface disease-related symptoms and signs in patients receiving AIs compared to healthy controls. This study may raise a flag regarding the use of AIs. However, further and larger prospective longitudinal studies are needed to examine the possible effect of AIs alone or in combination with chemotherapy in the eyes of breast cancer patients. © 2016 Wiley Periodicals, Inc.
ER -